Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa)

Neuropharmacology

Volumn 81, Issue , 2014, Pages 116-125

  Zhang, Li Ming ^a   Zhao, Nan ^a   Guo, Wen Zhi ^b   Jin, Zeng Liang ^a   Qiu, Zhi Kun ^a,c   Chen, Hong Xia ^a   Xue, Rui ^a   Zhang, You Zhi ^a   Yang, Ri Fang ^a   Li, Yun Feng ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antidepressant; Anxiolytic; Neurosteroids; The translocator protein 18KD; YL IPA08

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE RECEPTOR; CARRIER PROTEIN; DESIPRAMINE; DIAZEPAM; DULOXETINE; N ETHYL N (2 PYRIDINYLMETHYL) 2 (3,4 ICHLOROPHENYL) 7 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETAMIDE; PREGNENOLONE; PROGESTERONE; TRANSLOCATOR PROTEIN (18 KDA); UNCLASSIFIED DRUG; YL IPA08; 1-(2-METHOXY-4,6-BIS(METHOXYMETHOXY)PHENYL)-3-(3-NITROPHENYL)PROP-2-EN-1-ONE; CHALCONE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; ASTROCYTE; BINDING AFFINITY; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; MALE; MEMORY; MOTOR COORDINATION; MOUSE; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RAT; SLEEP; TRANQUILIZING ACTIVITY; ANALOGS AND DERIVATIVES; ANIMAL; ANXIETY; CONDITIONING; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; EXPLORATORY BEHAVIOR; INSTITUTE FOR CANCER RESEARCH MOUSE; MOTOR ACTIVITY; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; CHALCONE; CONDITIONING (PSYCHOLOGY); DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PROTEIN BINDING; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SWIMMING;

EID: 84896726084     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.09.016     Document Type: Article

References (51)

1. I.M. Anderson, I.N. Ferrier, R.C. Baldwin, P.J. Cowen, L. Howard, C. Lewis, K. Matthews, R.H. McAllister-Williams, R.C. Peveler, J. Scott, and A. Tylee Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines J. Psychopharmacol. 22 2008 343 396
2. D.S. Baldwin Clinical experience with paroxetine in social anxiety disorder Int. Clin. Psychopharmacol. Suppl 1 2000 S19 S24
3. D.S. Baldwin, I.M. Anderson, D.J. Nutt, B. Bandelow, A. Bond, J.R. Davidson, J.A. den Boer, N.A. Fineberg, M. Knapp, J. Scott, and H.U. Wittchen Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J. Psychopharmacol. 19 2005 567 596
4. A.M. Basso, K.B. Gallagher, J.P. Mikusa, and L.E. Rueter Vogel conflict test: sex differences and pharmacological validation of the model Behav. Brain Res. 218 2011 174 183
5. D. Bellelli, and J.J. Lambert Neurosteroids: endogenous regulators of the GABAA receptor Nat. Rev. Neurosci. 6 2005 565 575
6. A. Beurdeley-Thomas, L. Miccoli, S. Oudard, B. Dutrillaux, and M.F. Poupon The peripheral benzodiazepine receptors: a review J. Neurooncol. 46 2000 45 56
7. S.R. Bodnoff, B. Suranyi-Cadotte, D.H. Aitken, R. Quirion, and M.J. Meaney The effects of chronic antidepressant treatment in an animal model of anxiety Psychopharmacology (Berl) 95 1988 298 302
8. R.D. Brinton Neurosteroids as regenerative agents in the brain: therapeutic implications Nat. Rev. Endocrinol. 9 2013 241 250
9. M.K. Chen, and T.R. Guilarte Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair Pharmacol. Ther. 118 2008 1 17
10. B. Costa, E. Da Pozzo, and C. Martini Translocator protein as a promising target for novel anxiolytics Curr. Top. Med. Chem. 12 2012 270 285
11. S.C. Dulawa, and R. Hen Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test Neurosci. Biobehav. Rev. 29 2005 771 783
12. N.W. Dunham, and T.S. Miya A note on a simple apparatus for detecting neurological deficit in rats and mice J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim) 46 1957 208 209
13. D. Eser, T.C. Baghai, C. Schüle, C. Nothdurfter, and R. Rupprecht Neuroactive steroids as endogenous modulators of anxiety Curr. Pharm. Des. 14 2008 3525 3533
14. D. Eser, C. Schüle, T.C. Baghai, E. Romeo, D.P. Uzunov, and R. Rupprecht Neuroactive steroids and affective disorders Pharmacol. Biochem. Behav. 84 2006 656 666
15. E.C. Gavioli, F.S. Duarte, E. Bressan, P. Ferrara, R.C. Farges, and T.C. De Lima Antidepressant-like effect of Ro5-4864, a peripheral-type benzodiazepine receptor ligand, in forced swimming test Eur. J. Pharmacol. 471 2003 21 26
16. L.D. Griffin, and S.H. Mellon Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes Proc. Natl. Acad. Sci. U.S.A 9 1999 13512 13517
17. P. Guarneri, V. Papadopoulos, B. Pan, and E. Costa Regulation of pregnenolone synthesis in C6-2B glioma cells by 4'-chlorodiazepam Proc. Natl. Acad. Sci. U.S.A. 89 1992 5118 5122
18. A. Guidotti, E. Dong, K. Matsumoto, G. Pinna, A.M. Rasmusson, and E. Costa The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders Brain Res. Rev. 37 2001 110 115
19. P. Haddad The SSRI discontinuation syndrome J. Psychopharmacol. 12 1998 305 313
20. R.T. Khisti, C.T. Chopde, and S.P. Jain Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test Pharmacol. Biochem. Behav. 67 2000 137 143
21. A. Kita, H. Kohayakawa, T. Kinoshita, Y. Ochi, K. Nakamichi, S. Kurumiya, K. Furukawa, and M. Oka Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand Br. J. Pharmacol. 142 2004 1059 1072
22. A. Kita, and K. Furukawa Involvement of neurosteroids in the anxiolytic-like effects of AC-5216 in mice Pharmacol. Biochem. Behav. 89 2008 171 178
23. M. Mula Treatment of anxiety disorders in epilepsy: an evidence-based approach Epilepsia Suppl 1 2013 13 18 10.1111/epi.12101
24. E.M. Nelson, and A.M. Philbrick Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors Ann. Pharmacother. 46 2012 1712 1716
25. M.S. Nin, L.A. Martinez, F. Pibiri, M. Nelson, and G. Pinna Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression Front. Endocrinol. (Lausanne) 2 2011 73 doi: 10.3389
26. C. Nothdurfter, G. Rammes, T.C. Baghai, C. Schüle, M. Schumacher, V. Papadopoulos, and R. Rupprecht Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile J. Neuroendocrinol 24 2012 82 92
27. V. Papadopoulos, M. Baraldi, T.R. Guilarte, T.B. Knudsen, J.J. Lacapère, P. Lindemann, M.D. Norenberg, D. Nutt, A. Weizman, M.R. Zhang, and M. Gavish Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function Trends Pharmacol. Sci. 27 2006 402 409
28. V. Papadopoulos, L. Lecanu, R.C. Brown, Z. Han, and Z.X. Yao Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders Neuroscience 138 2006 749 756
29. G. Pinna In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants(SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis Behav. Pharmacol. 21 2010 438 450
30. G. Pinna, E. Costa, and A. Guidotti Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5- HT reuptake Psychopharmacology (Berl.) 186 2006 362 372
31. G. Pinna, E. Costa, and A. Guidotti SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake Curr. Opin. Pharmacol. 9 2009 24 30
32. G. Pinna, E. Costa, and A. Guidotti Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids Proc. Natl. Acad. Sci. U.S.A 101 2004 6222 6225
33. G. Pinna, E. Dong, K. Matsumoto, E. Costa, and A. Guidotti In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine Proc. Natl. Acad. Sci. U.S.A 100 2003 2035 2040
34. G. Pinna, and A.M. Rasmusson Upregulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioral deficits in a putative mouse model of PTSD J. Neuroendocrinol. 24 2012 102 116
35. R.D. Porsolt, G. Anton, N. Blavet, and M. Jalfre Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur. J. Pharmacol. 47 1978 379 391
36. G. Primofiore, F. Da Settimo, S. Taliani, F. Simorini, M.P. Patrizi, E. Novellino, G. Greco, E. Abignente, B. Costa, B. Chelli, and C. Martini N, N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor J. Med. Chem. 47 2004 1852 1855
37. J. Puia, J.M. Mienville, K. Matsumoto, E. Costa, and A. Guidotti On the putative physiological role of allopregnanolone on GABAA receptor function Neuropharmacology 44 2003 49 55
38. L. Rägo, V. Saano, T. Auvinen, A. Adojaan, R. Holma, and M.M. Airaksinen The effect of chronic treatment with peripheral benzodiazepine receptor ligands on behavior and GABAA/benzodiazepine receptors in rat Naunyn. Schmiedebergs. Arch. Pharmacol. 346 1992 432 436
39. P. Rocca, A.M. Beoni, C. Eva, P. Ferrero, E. Zanalda, and L. Ravizza Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients Biol. Psychiatry 43 1998 767 773
40. E. Romeo, J. Auta, A.P. Kozikowski, D. Ma, V. Papadopoulos, G. Puia, E. Costa, and A. Guidotti 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial J. Pharmacol. Exp. Ther. 262 1992 971 978
41. E. Romeo, S. Cavallaro, A. Korneyev, A.P. Kozikowski, D. Ma, A. Polo, E. Costa, and A. Guidotti Stimulation of brain steroidogenesis by 2-aryl-indole-3-acetamide derivatives acting at the mitochondrial diazepam-binding inhibitor receptor complex J. Pharmacol. Exp. Ther. 267 1993 462 471
42. R. Rupprecht, V. Papadopoulos, G. Rammes, T.C. Baghai, J. Fan, N. Akula, G. Groyer, D. Adams, and M. Schumacher Translocator protein (18 kDa) as a therapeutic target for neurological and psychiatric disorders Nat. Rev. Drug Discov. 9 2010 971 988
43. R. Rupprecht, G. Rammes, D. Eser, T.C. Baghai, C. Schüle, C. Nothdurfter, T. Troxler, C. Gentsch, H.O. Kalkman, F. Chaperon, V. Uzunov, K.H. McAllister, V. Bertaina-Anglade, C.D. La Rochelle, D. Tuerck, A. Floesser, B. Kiese, M. Schumacher, R. Landgraf, F. Holsboer, and K. Kucher Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects Science 24 2009 490 493
44. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, S. Dulawa, N. Weisstaub, J. Lee, R. Duman, O. Arancio, C. Belzung, and R. Hen Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805 809
45. C. Schüle, D. Eser, T.C. Baghai, C. Nothdurfter, J.S. Kessler, and R. Rupprecht Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience 191 2011 55 77
46. M. Serra, P. Madau, M.F. Chessa, M. Caddeo, E. Sanna, G. Trapani, M. Franco, G. Liso, R.H. Purdy, M.L. Barbaccia, and G. Biggio 2-Phenyl-imidazo[1,2- a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats Br. J. Pharmacol. 127 1999 177 187
47. R.D. Sheeler, M.J. Ackerman, E. Richelson, T.K. Nelson, J.P. Staab, E.G. Tangalos, L.M. Dieser, and J.L. Cunningham Considerations on safety concerns about citalopram prescribing Mayo. Clin. Proc. 87 2012 1042 1045
48. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology (Berl) 85 1985 367 370
49. S. Taliani, F. Da Settimo, E. Da Pozzo, B. Chelli, and C. Martini Translocator protein ligands as promising therapeutic tools for anxiety disorders Curr. Med. Chem. 16 2009 3359 3380
50. M. Verleye, Y. Akwa, P. Liere, N. Ladurelle, A. Pianos, B. Eychenne, M. Schumacher, and J.M. Gillardin The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain Pharmacol. Biochem. Behav. 82 2005 712 720
51. T. Zonda, G. Nagy, and D. Lester Panic disorder and suicidal behavior: a follow-up study of patients treated with cognitive therapy and SSRIs in Hungary Crisis 32 2011 169 172